Market News

ITUS (ITUS) Reaches $3.56 After 3.00% Up Move; Aurinia Pharmaceuticals Inchares (AUPH) Shorts Lowered By 10.53%

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Logo

The stock of ITUS Corporation (NASDAQ:ITUS) is a huge mover today! The stock increased 4.37% or $0.149 during the last trading session, reaching $3.559. About 101,837 shares traded. ITUS Corporation (NASDAQ:ITUS) has risen 11.12% since May 17, 2017 and is uptrending. It has underperformed by 0.43% the S&P500.The move comes after 9 months positive chart setup for the $59.19M company. It was reported on May, 17 by Barchart.com. We have $3.67 PT which if reached, will make NASDAQ:ITUS worth $1.78 million more.

Aurinia Pharmaceuticals Inchares (NASDAQ:AUPH) had a decrease of 10.53% in short interest. AUPH’s SI was 7.98M shares in May as released by FINRA. Its down 10.53% from 8.92M shares previously. With 988,500 avg volume, 8 days are for Aurinia Pharmaceuticals Inchares (NASDAQ:AUPH)’s short sellers to cover AUPH’s short positions. The SI to Aurinia Pharmaceuticals Inchares’s float is 17.22%. The stock decreased 4.40% or $0.28 during the last trading session, reaching $6.08. About 964,648 shares traded or 48.21% up from the average. Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) has declined 33.20% since May 17, 2017 and is downtrending. It has underperformed by 44.75% the S&P500.

More news for Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) were recently published by: Fool.com, which released: “Here’s Why Aurinia Pharmaceuticals Inc. Is Surging Today” on May 14, 2018. Seekingalpha.com‘s article titled: “Aurinia Pharmaceuticals’ (AUPH) CEO Richard Glickman on Q1 2018 Results – Earnings Call Transcript” and published on May 11, 2018 is yet another important article.

Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, engages in the development of a therapeutic drug to treat autoimmune diseases in Canada and internationally. The company has market cap of $507.63 million. The firm is developing Voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis. It currently has negative earnings. It has partnership agreements with Paladin Labs Inc. and 3SBio, Inc.

Among 6 analysts covering Aurinia Pharmaceuticals Inc (NASDAQ:AUPH), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Aurinia Pharmaceuticals Inc had 15 analyst reports since June 30, 2016 according to SRatingsIntel. The company was maintained on Monday, October 23 by Leerink Swann. Cantor Fitzgerald maintained Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) rating on Thursday, March 15. Cantor Fitzgerald has “Buy” rating and $16.0 target. The stock of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) has “Buy” rating given on Thursday, June 30 by H.C. Wainwright. The firm has “Buy” rating given on Monday, June 5 by Cantor Fitzgerald. On Tuesday, October 24 the stock rating was maintained by Canaccord Genuity with “Buy”. The firm has “Buy” rating by H.C. Wainwright given on Friday, December 30. The firm earned “Buy” rating on Monday, October 23 by Cantor Fitzgerald. The firm has “Speculative Buy” rating given on Wednesday, September 13 by Canaccord Genuity. Cantor Fitzgerald initiated the shares of AUPH in report on Tuesday, April 11 with “Overweight” rating. The rating was maintained by Cantor Fitzgerald on Friday, August 11 with “Buy”.

ITUS Corporation funds, develops, acquires, and licenses emerging technologies in the areas of biotechnology. The company has market cap of $59.19 million. The company, through its subsidiary, Anixa Diagnostics Corporation, is developing a platform called Cchek, a series of non-invasive, blood tests for the early detection of solid tumor based cancers. It currently has negative earnings. It has a collaborative research agreement with The Wistar Institute for the development and validation of Cchek.

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Ratings Chart

Leave a Reply

Your email address will not be published. Required fields are marked *